Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome

Area of Science:

• Oncology
• Immunology
• Medical Research

Background:

• Triple-negative breast cancer (TNBC) lacks estrogen/progesterone receptors and HER-2 amplification, limiting treatment options to chemotherapy.
• TNBC has a poor prognosis due to the absence of effective targeted therapies.
• Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has emerged as a treatment modality for TNBC.

Purpose of the Study:

• To explore the potential of immune combination therapy to improve efficacy and expand patient benefits in TNBC.
• To highlight the need for biomarkers to identify patient populations for combination therapy.
• To address the consideration of side effects in combination drug strategies.

Main Methods:

• Review of current findings on programmed cell death-(ligand) 1 (PD-(L)1) inhibitors in TNBC.
• Analysis of immunotherapy principles and TNBC tumor immune microenvironment (TIME) characteristics.
• Consideration of biomarker selection for targeted patient populations.

Main Results:

• Monotherapy with PD-(L)1 inhibitors demonstrates modest efficacy in TNBC.
• Only a small subset of TNBC patients benefits from current ICI monotherapy.
• Immune combination therapy is a promising strategy to enhance efficacy and broaden patient benefit.

Conclusions:

• Immune combination therapy holds significant promise for improving TNBC treatment outcomes.
• Effective biomarkers are crucial for identifying patients who will benefit from combination immunotherapy.
• Careful consideration of drug combinations and potential side effects is essential for successful implementation.